Reuters: Regulatory News: Abbott wins EU approval for new use of Humira drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Abbott wins EU approval for new use of Humira drug Apr 11th 2012, 05:00 April 11 | Wed Apr 11, 2012 1:00am EDT April 11 (Reuters) - Humira, the best-selling arthritis drug that forms the cornerstone of Abbott Laboratories' pharmaceutical business, has been approved in Europe for ulcerative colitis, the U.S. drugmaker said on Wednesday. The green light from the European Commission follows a positive opinion from the European Medicines Agency in February and marks the seventh indication for Humira in the European Union since its first approval in 2003. Humira, one of the world's biggest-selling drugs with sales forecast by analysts to be around $9 billion this year, is the first self-injectable biologic therapy for ulcerative colitis, a chronic disease that causes ulcers in the colon.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions